icon
icon
icon
icon
Upgrade
icon

Anastelica (ALPN-18.2) monoclonal antibody received a positive opinion for marketing authorisation in the EU

AInvestFriday, Jul 26, 2024 8:31 pm ET
1min read

AstraZeneca (Astellas Pharma, ALPMY.US) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of zolbetuximab for use in the European Union in combination with fluorouracil or platinum-based chemotherapy as first-line treatment for adult patients with locally advanced or metastatic HER2-negative gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) if CLDN18.2 is positive. If approved, zolbetuximab will be the first marketed CLDN18.2-targeting therapy in the European Union.

Zolbetuximab is a first-in-class monoclonal antibody targeting CLDN18.2 and was approved in Japan in March 2024, becoming the first CLDN18.2-targeting therapy to be approved by a regulatory agency globally.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.